
CLAIMS

What is claimed is:

1. A compound represented by formula (I);



Formula I,

or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, or prodrug thereof,

wherein ═══ represents a single or double bond;

q, r and s are independently 0 or 1, wherein at least one of q, r and s is 1;

t is 0 or 1;

n is 0, 1, 2, 3 or 4;

p is 0, 1 or 2;

X and Y are independently CR_1, $N(R_8)$, S or O, wherein when one of X and Y is CR_1, the other is $N(R_8)$, S or O;

G_1 is CR_1, S, O, NR_{10} or $NS(O)_2R_{10}$;

G_2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or, substituted or unsubstituted heterocyclic;

G_3 is substituted or unsubstituted C_1-C_8 alkyl, substituted or unsubstituted C_2-C_8 alkenyl, or, substituted or unsubstituted C_2-C_8 alkynyl;

each R_8 is independently hydrogen, acyl, aliphatic or substituted aliphatic;

each R_1 and R_2 is independently selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;

R_a is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;


R_b is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl;

or R_a and R_b, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclic group;


R_{10} is selected from hydrogen, hydroxy, amino, alkoxy, alkylamino, dialkylamino, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;

B is a linker; and


C is selected from:

(a) 


; where W is O or S; J is O, NH or NCH_3; and R_{31} is hydrogen or lower alkyl;

(b) 

; where W is O or S; Y_2 is absent, N, or CH; Z is N or CH; R_{32} and R_{34} are independently hydrogen, hydroxy, aliphatic group, provided that if R_{32} and R_{34} are both present, one of R_{32} or R_{34} must be hydroxy and if Y_2 is absent, R_{34} must be hydroxy; and R_{33} is hydrogen or aliphatic group;

(c) 


; where W is O or S; Y_1 and Z_1 are independently N, C or CH; and

(d) 

; where Z, Y_2, and W are as previously defined; R_{11} and R_{12} are independently selected from hydrogen or aliphatic; R_{21}, R_{22} and R_{23} are independently selected from hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.

2. A compound of claim 1 wherein B is selected from the group consisting of straight chain C_1-C_{10} alkyl, C_1-C_{10} alkenyl, C_1-C_{10} alkynyl, C_1-C_{10} alkoxy, alkoxyC_1-C_{10}alkoxy, C_1-C_{10} alkylamino, alkoxyC_1-C_{10}alkylamino, C_1-C_{10} alkylcarbonylamino, C_1-C_{10} alkylaminocarbonyl, aryloxyC_1-C_{10}alkoxy, aryloxyC_1-C_{10}alkylamino, aryloxyC_1-C_{10}alkylamino carbonyl, C_1-C_{10}-alkylaminoalkylaminocarbonyl, C_1-C_{10} alkyl(N-alkyl)aminoalkyl-aminocarbonyl, alkylaminoalkylamino, alkylcarbonylaminoalkylamino, alkyl(N-alkyl)aminoalkylamino, (N-alkyl)alkylcarbonylaminoalkylamino, alkylaminoalkyl, alkylaminoalkylaminoalkyl, alkylpiperazinoalkyl, piperazinoalkyl, alkylpiperazino, alkenylaryloxyC_1-C_{10}alkoxy, alkenylarylaminoC_1-C_{10}alkoxy, alkenylaryllalkylaminoC_1-C_{10}alkoxy, alkenylaryloxyC_1-C_{10}alkylamino, alkenylaryloxyC_1-C_{10}alkylaminocarbonyl, piperazinoalkylaryl, heteroarylC_1-C_{10}alkyl, heteroarylC_2-C_{10}alkenyl, heteroarylC_2-C_{10}alkynyl, heteroarylC_1-C_{10}alkylamino, heteroarylC_1-C_{10}alkoxy, heteroaryloxyC_1-C_{10}alkyl, heteroaryloxyC_2-C_{10}alkenyl, heteroaryloxyC_2-C_{10}alkynyl, heteroaryloxyC_1-C_{10}alkylamino and heteroaryloxyC_1-C_{10}alkoxy.

3. A compound of claim 1, represented by formula (II):




wherein X, Y, G_1, G_2, R_1, R_2, R_8, n, p, q, r, s, B and C are as defined as in claim 1.

4.A compound of claim 3, wherein G_2 is optionally substituted phenyl, pyridyl, pyrimidyl, indazolyl, pyrrolyl or benzimidazolyl.


5.A compound of claim 4, wherein G_2 is a phenyl, pyridyl, pyrimidyl, indazolyl, pyrrolyl or benzimidazolyl group, wherein said group is substituted by a

hydroxyl, hydroxymethyl, amino, acylamino, acetylamino or methylamino group.


6.A compound of claim 1, represented by formula (IV), (V), (VI) or (VII);




Formula IV



Formula V



Formula VI



Formula VII,

or the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts, or prodrugs thereof,

wherein ═══ represents a single or double bond;


G_1, G_2, R_1, R_2, R_8, n, p, q, r, s, B and C are as defined as in claim 1;

m is 0, 1, 2 or 3;

G_4 is NR_8, S or O;

R_3 is selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.


7.A compound of claim 6, wherein G_2 is selected from the group below:




wherein R_3, R_8 and m have the meanings set forth in claim 6.

8. A compound of claim 7, wherein m is 1 and R_3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino.


9. A compound of claim 1, represented by formula (X), (XI), (XII) or (XIII);




Formula X



Formula XI



Formula XII



Formula XIII,

or the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts, or prodrugs thereof,

wherein ═══ represents a single or double bond;

G_1, G_2, R_1, R_2, R_8, n, p, q, r, s, B and C are as defined in claim 1;


m is 0, 1, 2 or 3;

R_3 is selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;

G_4 is NR_8, S or O; and

o is 1, 2, 3, 4, 5, 6, 7 or 8.


10. A compound of claim 9, wherein G_2 is selected from the group below:




wherein R_3, R_8 and m have the meanings set forth in claim 9.

11. A compound of claim 10, wherein m is 1 and R_3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino.


12. A compound of claim 1, represented by formula (XIV), (XV), (XVI) or (XVII);




Formula XIV



Formula XV



Formula XVI




Formula XVII,

wherein G_1, G_2, n, p, B, C, R_1, R_2, and R_8 are as defined in claim 1;

m is 0, 1, 2 or 3; and

R_3 is selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.


13. A compound of claim 12, wherein G_2 is selected from the group below:




wherein R_3, R_8 and m have the meanings set forth in claim 6.

14. A compound of claim 13, wherein m is 1 and R_3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino.

15. A compound of claim 1, represented by formula XVIII or XIX;



XVIII




XIX,

wherein G_2, n, p, B, C, R_1, R_2, and R_8 are as defined in claim 1;

m is 0, 1, 2 or 3; and

R_3 is selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.


16. A compound of claim 15, wherein G_2 is selected from the group below:




wherein R_3, R_8 and m have the meanings set forth in claim 6.

17. A compound of claim 16, wherein m is 1 and R_3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino.

18. A compound of claim 1, 3, 6, 9, 12 or 15, wherein B is selected from:




and




wherein d and e are independently 0, 1, 2, 3, 4, 5, 6, 7 or 8; and R_{100} is selected from hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl and C_3-C_8 cycloalkyl.

19. A compound of claim 15, wherein C is –C(O)N(H)OH.

20. A compound of claim 1, represented by formula XX or XXI;



Formula XX



Formula XXI,

wherein n, m, p, Y_2, W, Z, G_1, G_2, G_4, R_1, R_2, R_3, R_8, R_{32}, R_{33} and R_{34} are as defined in claim 1;


G_4 is NR_8, S or O;

m is 0, 1, 2 or 3;

R_3 is selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;

M_1 is absent, O, S, NR_8, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, heterocyclic, SO, SO_2 or C=O; M_2 is absent, C_1-C_6 alkyl, O, NR_8, heterocyclic, aryl, heteroaryl, or C=O; M_3 is absent, O, NR_8, S, SO, SO2, CO, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, or heterocyclic; M_4 is absent, O, NR_8, heteroaryl, heterocyclic or aryl; and M_5 is absent, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8alkynyl, heteroaryl, heterocyclic or aryl.


21. A compound of claim 20, wherein G_2 is selected from the group below:




wherein R_3, R_8 and m have the meanings set forth in claim 6.

22. A compound of claim 21, wherein m is 1 and R_3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino.

23. A compound of claim 1, represented by formula XXII or XXIII;



Formula XXII



Formula XXIIII,

wherein G_1, G_2, n, p, R_1, R_2, R_5, R_8 are as defined in claim 1;

t, v and w are independently 0, 1, 2 or 3;

u is 0, 1, 2, 3, 4, 5, 6, 7 or 8;

m is 0, 1, 2 or 3;

G_4 is NR_8, S or O;


G_5 is absent, C_1-C_8 alkyl or a C_1-C_8 alkyl interrupted by one or more O, S, S(O), SO_2, $N(R_8)$, C(O);

G_6 is selected from CR_1 or NR_8;

G_7 is selected from $-CR_1$, $-NR_8$, S or O; and

R_5 and R_6 are independently selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.


24. A compound of claim 23, wherein G_2 is selected from the group below:




wherein R_3, R_8 and m have the meanings set forth in claim 6.

25. A compound of claim 24, wherein m is 1 and R_3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino.

26. A compound of claim 1 represented by formula XXIV or XXV:



Formula XXIV



Formula XXV

wherein G_1, G_2, n, p, R_1, R_2 and R_8 are as defined in claim 1;

w and m are each independently 0, 1, 2 or 3;

u is 0, 1, 2, 3, 4, 5, 6, 7 or 8;


G_4 is NR_8, S or O;

G_5 is absent, C_1-C_8 alkyl or a C_1-C_8 alkyl interrupted by one or more O, S, S(O), SO_2, N(R_8), C(O);

R_3 and R_4 are independently selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic; and

R_6 is selected from absent, hydrogen, hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic.

27. A compound of claim 26, wherein G_2 is selected from the group below:











wherein R_3, R_8 and m have the meanings set forth in claim 6.






28. A compound of claim 27, wherein m is 1 and R_3 is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino.






29. A compound according to Claim 1 selected from the compounds delineated in Table A or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, or prodrug thereof:






Table A






Compound No.	Structure
1	
2	
3	






4	
5	
6	
7	
8	






9	
10	
11	
12	
13	






14	
15	
16	
17	
18	






19	
20	
21	
22	
23	






24	
25	
26	
27	
28	






29	
30	
31	
32	
33	






34	
35	
36	
37	
38	






39	
40	
41	
42	
43	






44	
45	
46	
47	
48	






49	
50	
51	
52	
53	






54	
55	
56	
57	
58	






59	
60	
61	
62	
63	






64	
65	
66	
67	
68	






69	
70	
71	
72	
73	






74	
75	
76	
77	
78	






79	
80	
81	
82	
83	






84	
85	
86	
87	
88	






89	
90	
91	
92	
93	






94	
95	
96	
97	
98	






99	
100	
101	
102	
103	






104	
105	
106	
107	
108	






109	
110	
111	
112	
113	






114	
115	
116	
117	
118	






119	
120	
121	
122	
123	






124	
125	
126	
127	
128	






129	
130	
131	
132	
133	






134	
135	
136	
137	
138	






139	
140	
141	
142	
143	






144	
145	
146	
147	
148	






149	
150	
151	
152	
153	






154	
155	
156	
157	
158	






159	
160	
161	
162	
163	






164	
165	
166	
167	
168	






169	
170	
171	
172	
173	






174	
175	
176	
177	
178	






179	
180	
181	
182	
183	






184	
185	
186	
187	
188	



189	
190	
191	
192	
193	

194	
195	
196	
197	
198	

199	
200	
201	
202	
203	

204	
205	
206	
207	
208	

209	
210	
211	
212	
213	

214	
215	

30. A pharmaceutical composition comprising as an active ingredient a compound of Claim 1 and a pharmaceutical acceptable carrier.

31. A method of treating a PI3K related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 30.

32. The method of claim 31, wherein said PI3K related disease or disorder is a cell proliferative disorder.

33. The method of claim 32, wherein said cell proliferative disorder is selected from the group consisting of papilloma, blastoglioma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease.


34. A method of treating an mTOR-mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 30.

35. A method of treating an HDAC-mediated disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 30.


36. A method of treating both PI3K and HDAC mediated diseases comprising administering to a subject in need thereof a pharmaceutical composition of claim 30.

WE CLAIM:

1. A compound represented by formula (XIV) or (XV):



(XIV)



(XV)

or a pharmaceutically acceptable salt thereof,

B is a straight- or branched-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, or alkynylheteroaryl, in which one or more methylenes can be interrupted or terminated by O, S, S(O), SO_2, $N(R_8)$, C(O), aryl, heteroaryl, or heterocyclic;

n is 0, 1, 2, 3 or 4;

p is 0 or 1;

G_1 is CHR_1, S, O, NR_{10} or $NS(O)_2R_{10;}$

G_2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or, substituted or unsubstituted heterocyclic;


each R_1 and R_2 is independently hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic;

each R_8 is independently hydrogen, acyl, or aliphatic of 4 to 12 atoms;

R_{10} is hydrogen, hydroxy, amino, alkoxy, alkylamino, dialkylamino, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic;


G_4 is S; and

C is



; where R_{33} is hydrogen or C_1-C_8-alkyl.

2. The compound of claim 1 wherein G_2 is




wherein:

represents a single or double bond;

R_3 is hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic; and


m is 0, 1, 2 or 3.

3. The compound of claim 1, wherein G_2 is



wherein each R_3 is hydroxyl, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic;
m is 0, 1, 2 or 3; and
R_8 is hydrogen, acyl, or aliphatic of 4 to 12 atoms.


4. The compound of claim 1, wherein G_2 is



wherein m is 1 and R_3 is hydroxy, hydroxymethyl, amino, acylamino, acetylamino or methylamino.

5. The compound of any one of claims 1 to 4, wherein B is straight chain C_2-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_1-C_{10} alkoxy, alkoxyC_1-C_{10}alkoxy, C_1-C_{10} alkylamino, alkoxyC_1-C_{10}alkylamino, C_1-C_{10} alkylcarbonylamino, C_1-C_{10} alkylaminocarbonyl, aryloxyC_1-C_{10}alkoxy, aryloxyC_1-C_{10}alkylamino, aryloxyC_1-C_{10}alkylamino carbonyl, C_1-C_{10}-alkylaminoalkylaminocarbonyl, C_1-C_{10} alkyl(N-alkyl)aminoalkyl-aminocarbonyl, alkylaminoalkylamino, alkylcarbonylaminoalkylamino, alkyl(N-alkyl)aminoalkylamino, (N-alkyl)alkylcarbonylaminoalkylamino, alkylaminoalkyl, alkylaminoalkylaminoalkyl, alkylpiperazinoalkyl, piperazinoalkyl, alkylpiperazino, alkenylaryloxyC_1-C_{10}alkoxy, alkenylarylaminoC_1-C_{10}alkoxy, alkenylaryllalkylaminoC_1-C_{10}alkoxy, alkenylaryloxyC_1-C_{10}alkylamino, alkenylaryloxyC_1-C_{10}alkylaminocarbonyl, piperazinoalkylaryl, heteroarylC_1-C_{10}alkyl, heteroarylC_2-C_{10}alkenyl, heteroarylC_2-C_{10}alkynyl, heteroarylC_1-C_{10}alkylamino, heteroarylC_1-C_{10}alkoxy, heteroaryloxyC_1-C_{10}alkyl, heteroaryloxyC_2-C_{10}alkenyl, heteroaryloxyC_2-C_{10}alkynyl, heteroaryloxyC_1-C_{10}alkylamino or heteroaryloxyC_1-C_{10}alkoxy.


6. The compound of claim 1, represented by formula (XIV):



(XIV)

wherein G_1, G_2, n, p, B, C, R_1, R_2 and R_8 are as defined in claim 1.

7. The compound of claim 6 wherein G_2 is




wherein:

represents a single or double bond;

R_3 is hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic; and

m is 0, 1, 2 or 3.

8. The compound of claim 6, wherein G_2 is




wherein each R_3 is hydroxyl, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic;

m is 0, 1, 2 or 3; and


R_8 is hydrogen, acyl, or aliphatic of 4 to 12 atoms.






9. The compound of claim 6, wherein G_2 is



wherein m is 1 and R_3 is hydroxy, hydroxymethyl, amino, acylamino, acetylamino or methylamino.


10. The compound of any one of claims 1, 2, 3, 4, 6, 7, 8 or 9, wherein B is




,

,

,

, or

,


wherein d and e are independently 0, 1, 2, 3, 4, 5, 6, 7 or 8; and R_{100} is hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl or C_3-C_8 cycloalkyl.

11. The compound of claim 10, wherein B is


,

wherein R_{100} is hydrogen or methyl.

12. A compound represented by Formula (XX):



(XX)

wherein;

n is 0, 1, 2, 3 or 4;

p is 0 or 1;

G_1 is CHR_1, S, O, NR_{10} or $NS(O)_2R_{10;}$

G_2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or, substituted or unsubstituted heterocyclic;

G_4 is S or O;

each R_1 and R_2 is independently hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, or substituted heterocyclic;

each R_8 is independently hydrogen, acyl, or aliphatic of 4 to 12 atoms;

R_{10} is hydrogen, hydroxy, amino, alkoxy, alkylamino, dialkylamino, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, or R_3 is hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, or substituted heterocyclic;

R_{33} is H or C_1-C_8-alkyl;

R_{34} is OH;


W is O;

Y_2 and R_{32} are both absent;

Z is N;

M_1 is absent, O, S, NR_8, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, heterocyclic, SO, SO_2 or C=O; M_2 is absent, C_1-C_6 alkyl, O, NR_8, heterocyclic, aryl, heteroaryl, or C=O; M_3 is absent, O, NR_8, S, SO, SO2, CO, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, or heterocyclic; M_4 is absent, O, NR_8, heteroaryl, heterocyclic or aryl; and M_5 is C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8alkynyl, heteroaryl, heterocyclic or aryl.

13. The compound of claim 12 wherein G_2 is




wherein:

represents a single or double bond;

R_3 is hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic; and

m is 0, 1, 2 or 3.

14. The compound of claim 12, wherein G_2 is




wherein each R_3 is hydroxyl, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic;

m is 0, 1, 2 or 3; and


R_8 is hydrogen, acyl, or aliphatic of 4 to 12 atoms.

15. The compound of claim 12, wherein G_2 is



wherein m is 1 and R_3 is hydroxy, hydroxymethyl, amino, acylamino, acetylamino or methylamino.

16. A compound of claim 1, represented by Formula (XXII):



(XXII)

wherein G_1, G_2, n, p, R_1, R_2, and R_8 are as defined in claim 1;

t, v and w are independently 0, 1, 2 or 3;

u is 0, 1, 2, 3, 4, 5, 6, 7 or 8;

G_4 is S or O;


G_5 is absent, C_1-C_8 alkyl or a C_1-C_8 alkyl interrupted by one or more O, S, S(O), SO_2, $N(R_8)$, C(O);

G_6 is CR_1 or N;

G_7 is $–CHR_1$, $-NR_8$, S or O; and

R_5 and R_6 are independently hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic, substituted aliphatic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, or substituted heterocyclic.

17. The compound of claim 14 wherein G_2 is




wherein:

represents a single or double bond;

R_3 is hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic; and


m is 0, 1, 2 or 3.

18. The compound of claim 16, wherein G_2 is




wherein each R_3 is hydroxyl, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic;
m is 0, 1, 2 or 3; and
R_8 is hydrogen, acyl, or aliphatic of 4 to 12 atoms.

19. The compound of claim 16, wherein G_2 is



wherein m is 1 and R_3 is hydroxy, hydroxymethyl, amino, acylamino, acetylamino or methylamino.

20. A compound of claim 1 represented by formula XXIV:



(XXIV),

wherein G_1, G_2, n, p, R_1, R_2 and R_8 are as defined in claim 1;

w is 0, 1, 2 or 3;

u is 0, 1, 2, 3, 4, 5, 6, 7 or 8;

G_4 is S or O;

G_5 is absent, C_1-C_8 alkyl or a C_1-C_8 alkyl interrupted by one or more O, S, S(O), SO_2, $N(R_8)$, and C(O); and

each R_6 is amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic.

21. A compound of claim 20, wherein:

G_1 is O;


G_2 is optionally substituted phenyl, pyridyl, pyrimidyl,

indazolyl, pyrrolyl or benzimidazolyl;

G_5 is $–N(R_8)$-C_1-C_4-alkyl; and

u is 0.

22. The compound of claim 20 or claim 21 wherein G_2 is




,

wherein:

represents a single or double bond;


R_3 is hydroxy, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic; and
m is 0, 1, 2 or 3.

23. A compound of claim 20 or claim 21, wherein G_2 is








wherein each R_3 is hydroxyl, amino, halogen, alkoxy, alkylamino, dialkylamino, CF_3, CN, NO_2, sulfonyl, acyl, aliphatic of 4 to 12 atoms, aryl, heteroaryl or heterocyclic;
m is 0, 1, 2 or 3; and
R_8 is hydrogen, acyl, or aliphatic of 4 to 12 atoms.







24. The compound of claim 20 or 21, wherein G_2 is















wherein m is 1 and R_3 is hydroxy, hydroxymethyl, amino, acylamino, acetylamino or methylamino.







25. A compound selected from the compounds set forth in Table A:
Table A







Compound No.	Structure
10	
11	
12	
13	
14	







15	
16	
17	
18	
19	
20	







21	
22	
23	
24	
25	
26	







27	
28	
41	
42	
43	
44	







45	
46	
47	
48	
49	
50	







51	
52	
53	
54	
55	
56	






57	
58	
59	
60	
61	
62	






63	
64	
65	
66	
67	
68	







69	
70	
71	
72	
73	
74	







75	
76	
77	
78	
79	
80	







81	
82	
83	
84	
85	
86	







87	
88	
89	
90	
91	







92	
93	
94	
95	
96	







97	
98	
99	
100	
101	
102	








103	
104	
105	
106	
107	
108	








109	
110	
111	
112	
113	
114	







115	
116	
117	
118	
119	
120	







121	
122	
123	
124	
125	
126	







127	
128	
129	
130	
131	
132	








133	
134	
135	
136	
137	
138	
139	







140	
141	
142	
143	
144	
145	
146	







147	
148	
149	
150	
151	
152	







153	
154	
155	
156	
157	
158	







159	
160	
161	
162	
163	
164	







165	
166	
167	
168	
169	
170	
171	







172	
173	
174	
175	
176	
177	







178	
179	
180	
181	
182	
183	



184	
185	
186	
187	
188	
189	

190	
191	
192	
193	
194	
195	

196	
197	
198	
199	
200	
201	


202	
203	
204	
205	
206	
207	

208	
209	
210	
211	
212	
213	

214	 or
215	

or a pharmaceutically acceptable salt thereof.


26. A compound of the formula:



,

or a pharmaceutically acceptable salt thereof.

27. A compound of the formula:



,

or a pharmaceutically acceptable salt thereof.

28. A pharmaceutical composition comprising a compound of any one of claims 1 to 27 and a pharmaceutically acceptable carrier.

29. Use of a compound of any one of claims 1 to 27 in the manufacture of a medicament for treating a PI3K related disease or disorder in a subject in need thereof.

30. The use of claim 29, wherein the disease or disorder is a cell proliferative disorder.

31. The use of claim 30, wherein the disease or disorder is papilloma, glioblastoma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease or Burkitt's disease.

32. Use of a compound of any one of claims 1 to 27 in the manufacture of a medicament for treating an HDAC-mediated disease in a subject in need thereof.

33. Use of a compound of any one of claims 1 to 27 in the manufacture of a medicament for treating a disease mediated by both PI3K and HDAC in a subject in need thereof.

34. A compound of any one of claims 1 to 27 for use in treating a PI3K related disease or disorder in a subject in need thereof.

35. The compound for use of claim 34, wherein the disease or disorder is a cell proliferative disorder.

36. The compound for use of claim 35, wherein the disease or disorder is papilloma, glioblastoma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease or Burkitt's disease.

37. A compound of any one of claims 1 to 27 for use in treating an HDAC-mediated disease in a subject in need thereof.

38. A compound of any one of claims 1 to 27 for use in treating a disease mediated by both PI3K and HDAC in a subject in need thereof.